A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor

The HIV-1 Tat protein is a promising target for AIDS therapy, due to its extra-cellular roles against the immune system. From the 2D-NMR structure of Tat, we have designed molecules, called TDS, able to bind to Tat and inhibit HIV-1 replication in vitro. This new family of antivirals is composed of...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 14; no. 6; pp. 1543 - 1546
Main Authors Montembault, Mickaël, Vo-Thanh, Giang, Deyine, Abdallah, Fargeas, Valérie, Villiéras, Monique, Adjou, Ané, Dubreuil, Didier, Esquieu, Didier, Grégoire, Catherine, Opi, Sandrine, Péloponèse, Jean-Marie, Campbell, Grant, Watkins, Jennifer, de Mareuil, Jean, Aubertin, Anne-Marie, Bailly, Christian, Loret, Erwann, Lebreton, Jacques
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 22.03.2004
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The HIV-1 Tat protein is a promising target for AIDS therapy, due to its extra-cellular roles against the immune system. From the 2D-NMR structure of Tat, we have designed molecules, called TDS, able to bind to Tat and inhibit HIV-1 replication in vitro. This new family of antivirals is composed of a triphenylene aromatic ring substituted with at least one carbon chain bearing a succinimide group. These ligands are prepared from triphenylene or 2,6,10-trimethylphenylene in 3–6 steps depending on the target molecule. A new family of antivirals able to bind on protein Tat and inhibit in vitro HIV-1 replication has been synthesized.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2003.12.095